A new pet scan for pancreatic neuroendocrine tumors
Treatments studied
Part of Blood & lymphatic, Cancer, Digestive system, Hormones & metabolism, Immune system & allergy clinical trials.
This study is testing a special type of PET/CT scan using a tracer called FTT to see if it can better find and track pancreatic neuroendocrine tumors that have spread or cannot be removed by surgery. The goal is to improve imaging for people with this type of cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a pancreatic neuroendocrine tumor that is grade 1, 2, or 3 and has spread or cannot be removed by surgery.
- You must have at least one tumor that is 1.5 cm or larger seen on a previous scan (like CT, MRI, or PET).
- You can be on treatment or not on treatment for your cancer.
- You must be willing to provide a sample of your tumor tissue (from a previous biopsy or surgery) if available.
- You must be able to understand and give written informed consent to take part in the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests how well an FTT PET/CT scan can detect and measure metastatic (spread) prostate cancer. It may help your care team decide on the best next treatment plan, especially if you need to change or start therapy.
This early study uses a special PET/CT scan to see how much a specific cancer-related protein (PARP-1) is present in pheochromocytoma and paraganglioma. It may help doctors understand the biology of these tumors and how useful this scan could be in the future.
This study tests a new type of PET scan that uses a radioactive tracer called FAPI-74 to find cancer spread in people with pancreatic cancer. The goal is to see if this scan can help doctors better plan treatment.
This trial tests two new radioactive imaging scans (called PET scans) designed to better detect certain advanced cancers like pancreatic, lung, breast, colon, or soft-tissue tumors. The goal is to see if these scans help doctors find and track cancer more accurately than standard imaging.
This trial tests a new type of PET/CT scan called [68Ga]Ga-FAPI-04 to see if it can better detect high-grade neuroendocrine tumors. It is for patients whose standard scans show low uptake or who have aggressive tumor features.
This trial uses a special PET scan (68Ga-grazytracer) to see how well immunotherapy is working for pancreatic cancer. It may help your doctor understand if your treatment is effective.
Hear when a new Neuroendocrine Carcinoma Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.